BIOMAT Database Logo BIOMAT Database Logo

Fibrinolytic and thrombolytic parameters in patients with deep vein thrombosis treated by low molecular weight and standard heparin. 1989

R Faivre, and E Neuhart, and M Mirshahi, and M Mirshahi, and C Soria, and J Soria, and J P Bassand, and J P Caen, and J P Maurat
Service de Cardiologie et Laboratoire d'Hemostase, CHU St-Jacques, Besancon, France.

UI MeSH Term Description Entries
D007118 Immunoassay A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance. Immunochromatographic Assay,Assay, Immunochromatographic,Assays, Immunochromatographic,Immunoassays,Immunochromatographic Assays
D010690 Phlebography Radiographic visualization or recording of a vein after the injection of contrast medium. Venography,Phlebographies,Venographies
D011655 Pulmonary Embolism Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS. Pulmonary Thromboembolism,Thromboembolism, Pulmonary,Embolism, Pulmonary,Embolisms, Pulmonary,Pulmonary Embolisms,Pulmonary Thromboembolisms,Thromboembolisms, Pulmonary
D005338 Fibrin Fibrinogen Degradation Products Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis. Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006495 Heparin, Low-Molecular-Weight Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism. LMWH,Low-Molecular-Weight Heparin,Low Molecular Weight Heparin,Heparin, Low Molecular Weight
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013924 Thrombophlebitis Inflammation of a vein associated with a blood clot (THROMBUS). Phlegmasia Alba Dolens,Dolens, Phlegmasia Alba,Thrombophlebitides

Related Publications

R Faivre, and E Neuhart, and M Mirshahi, and M Mirshahi, and C Soria, and J Soria, and J P Bassand, and J P Caen, and J P Maurat
Low-molecular-weight heparin in patients with deep-vein thrombosis.
July 2001, The New England journal of medicine,
R Faivre, and E Neuhart, and M Mirshahi, and M Mirshahi, and C Soria, and J Soria, and J P Bassand, and J P Caen, and J P Maurat
Low-molecular-weight heparin in patients with deep-vein thrombosis.
July 2001, The New England journal of medicine,
R Faivre, and E Neuhart, and M Mirshahi, and M Mirshahi, and C Soria, and J Soria, and J P Bassand, and J P Caen, and J P Maurat
Low-molecular-weight heparin and deep-vein thrombosis.
April 1987, The New England journal of medicine,
R Faivre, and E Neuhart, and M Mirshahi, and M Mirshahi, and C Soria, and J Soria, and J P Bassand, and J P Caen, and J P Maurat
Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.
February 1992, Lancet (London, England),
R Faivre, and E Neuhart, and M Mirshahi, and M Mirshahi, and C Soria, and J Soria, and J P Bassand, and J P Caen, and J P Maurat
Low molecular weight heparin for deep vein thrombosis in glioma patients.
October 2002, Journal of neurology,
R Faivre, and E Neuhart, and M Mirshahi, and M Mirshahi, and C Soria, and J Soria, and J P Bassand, and J P Caen, and J P Maurat
Rapid lysis of deep vein thrombosis by low molecular weight heparin.
January 2000, Texas Heart Institute journal,
R Faivre, and E Neuhart, and M Mirshahi, and M Mirshahi, and C Soria, and J Soria, and J P Bassand, and J P Caen, and J P Maurat
Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis.
February 1982, British medical journal (Clinical research ed.),
R Faivre, and E Neuhart, and M Mirshahi, and M Mirshahi, and C Soria, and J Soria, and J P Bassand, and J P Caen, and J P Maurat
Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin.
September 2002, British journal of haematology,
R Faivre, and E Neuhart, and M Mirshahi, and M Mirshahi, and C Soria, and J Soria, and J P Bassand, and J P Caen, and J P Maurat
Treatment of upper limb deep vein thrombosis with low molecular weight heparin.
May 2003, American journal of physical medicine & rehabilitation,
R Faivre, and E Neuhart, and M Mirshahi, and M Mirshahi, and C Soria, and J Soria, and J P Bassand, and J P Caen, and J P Maurat
Thrombolysis and fibrinolytic parameters during heparin treatment of deep vein thrombosis.
September 1985, Thrombosis research,
Copied contents to your clipboard!